Ardelyx (ARDX) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Ardelyx (ARDX) over the past year, gaining 23.1% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -71.4% for LXRX. Ardelyx is the larger company by market cap ($844.3 million vs $783.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | LXRX |
|---|---|---|
| Share price | $3.27 | $1.76 |
| Market cap | $844.27M | $783.12M |
| 1-day change | +0.31% | 0.00% |
| YTD return | -43.91% | +53.04% |
| 1-year return | -35.38% | +23.08% |
| 5-year return | +202.78% | -71.43% |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $2.68 |
| 52-week low | $3.18 | $1.10 |
| Distance from 52-week high | -61.07% | -34.33% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +294.50% | +158.52% |
| Average volume | 4.17M | 2.90M |
| Shares outstanding | 258.19M | 444.96M |
| Employees | 489 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed ARDX by 58.5 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
ARDX vs LXRX FAQ
Which is bigger, Ardelyx or Lexicon Pharmaceuticals?
Ardelyx (ARDX) is larger, with a market capitalization of $844.27M compared with $783.12M for Lexicon Pharmaceuticals (LXRX).
Which stock has performed better over the past year, ARDX or LXRX?
LXRX returned +23.08% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.